Methylation and Expression Status of The CpG-Island of SMG1 Promoter in Acute Myeloid Leukemia: A Follow-Up Study in Patients

(Pages: 163-169)

Neda Karami, M.Sc, ¹Mohammad Hossein Ahmadi, Ph.D, ²Saeed Mohammadi, Ph.D, ³Amirhosein Maali, M.Sc, ^1,4Ahad Alizadeh, Ph.D., ⁵Shaghayegh Pishkhan Dibazar, M.Sc., ⁶Mehdi Azad, Ph.D., ^2,*

1.-Department of Medicine Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Science, Qazvin, Iran

2.-Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

3.-Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital of Tehran, Tehran, Iran

4.-Department of Immunology, Pasteur Institute of Iran, Tehran, Iran

5.-Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran

6.-Department of Immunology, Tarbiat Modares University, Tehran, Iran

*Corresponding Address: P.O.Box: 34197-59811 Department of Medical Laboratory Sciences Faculty of Allied Medicine Qazvin University of Medical Sciences Qazvin Iran Email:haematologicca@gmail.com

Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Karami Neda, Ahmadi Mohammad Hossein, Mohammadi Saeed, Maali Amirhosein, Alizadeh Ahad, Pishkhan Dibazar Shaghayegh, Azad Mehdi. Methylation and Expression Status of The CpG-Island of SMG1 Promoter in Acute Myeloid Leukemia: A Follow-Up Study in Patients . Cell J. 2022; 24(4): 163-169.

Abstract

Objective

Aberrant alterations in DNA methylation are known as one of the hallmarks of oncogenesis and play a vital role in the progression of acute myeloid leukemia (AML). SMG1 is a member of the Phosphoinositide 3-kinases family, acting as a tumor suppressor gene. The aim of this study was the evaluation of the expression level and methylation status of SMG1 in AML.

Materials and Methods

In this follow-up study on AML patients admitted to Shariati Hospital, Tehran, Iran, the methylation status of SMG1 [performed by methylation-specific polymerase chain reaction (PCR)] and its expression level (performed by qRT-PCR) were evaluated in three phases: newly diagnosed, under treatment and complete remission. The correlation of the methylation status of SMG1, its expression level, and clinical/paraclinical data was analyzed by SPSS ver.25.

Results

This study on 18 patients and five control individuals showed that the CpG-islands of the SMG1 promoter in newly diagnosed cases is hypomethylated compared to the normal group (P=0.002) The fold change of SMG1 expression levels in new cases is 0.464 ± 0.468, while the fold change of SMG1 expression levels in under-treatment and in-remission patients is 0.973 ± 1.159 and 0.685 ± 0.885, respectively. In under-treatment patients, white blood cell (WBC) count decreases 114176.36 cell/µl with each unit of increase in fold change of SMG1 (P<0.0001), and Hb unit increases 2.062 g/dl with each unit of increase in fold change (P<0.0001) Also, in the remission phase, the Hb unit increases 1.395 g/dl with each unit increase in fold change (P=0.019).

Conclusion

The robust results of our study suggest that the methylation and expression of have a high impact on the pathogenesis of AML. Also, the methylation and expression of SMG1 can play a prognostic role in AML.

Keywords:

Emails

Phone